2008-10-10 13:02:44 - Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report analysing targeted therapy for cancer.

'Commercial Insight: Targeted Therapy Cancer Brands', which is available at www.reportbuyer.com/go/DAT13059 forecasts that this market will continue to perform strongly over the coming years, achieving sales of over $42 billion by 2017.

The report shows that since the first approval of a targeted therapy for cancer just over ten years ago, targeted therapies have notably

improved treatment outcomes in cancer, becoming the leading therapy class in the oncology market.

It further shows that Genentech/Roche will continue to dominate the market, with its top three targeted therapies - Rituxan, Herceptin and Avastin - alone representing more than half of the total targeted therapies market value.

Authors of the report note that an increasing number of companies have turned their attention to the cancer targeted therapy market, undoubtedly trying to emulate the blockbuster status that several brands have already achieved. Since 2005, ten new branded targeted drugs have entered the market. With more pipeline drugs looking likely to gain approval in the near future, the market is set to become even more competitive and fragmented.

Several factors will drive continuing market penetration by the targeted therapy cancer brands, including growing physician awareness of recently launched brands, use in earlier lines of therapy and different treatment settings such as the adjuvant and maintenance settings.

The report forecasts some of the key targeted therapies to achieve high sales growth between 2008 and 2017, driven by these factors. As a result, eight new targeted therapy cancer brands will achieve blockbuster status by 2017, including Pfizer's Sutent (sunitinib), OSI/Genentech/Roche/Chugai's Tarceva (erlotinib) and Bayer Schering/Onyx's Nexavar (sorafenib).

The report 'Commercial Insight: Targeted Therapy Cancer Brands?' is available from Report Buyer at: www.reportbuyer.com/pharma_healthcare/healthcare/commercial_insi ..

Report Buyer product ID: DAT13059

About Report Buyer.

Report Buyer (www.reportbuyer.com/pharma_healthcare/index.html) is a UK-based independent online store supplying business information. The website now carries over 85,000 business information products, including market reports, studies, books and events. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. A regularly updated blog provides information on the latest market trends.